1. Per slide 13, IDIX sees the strongest synergy in a pre-clinical DAA combo from a PI+ NS5A inhibitor + a purine nuke. Going from strongest to weakest synergy is as follows:
A. PI + NS5A inhibitor + purine nuke B. PI + non-nuke + purine nuke C. PI + pyrimidine nuke + purine nuke D. PI + NS5A E. PI + non-nuke F. PI + pyrimidine nuke
2. IDX320 should treat HCV genotypes 1, 2a, and 4a with a qD dose. However, IDIX expects BID dosing will be necessary for genotype 3a.
3. IDIX has sufficient cash to fund operations into 2H11 and that's assuming nothing on the partnership or milestone front.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.